Sumitomo Mitsui Trust Group Inc. Boosts Stock Position in Omnicell, Inc. $OMCL

Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 2.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,410,865 shares of the company’s stock after acquiring an additional 27,497 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Omnicell were worth $47,095,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Raymond James Financial Inc. purchased a new position in Omnicell during the second quarter valued at approximately $26,000. Clearstead Advisors LLC increased its stake in shares of Omnicell by 12,180.0% in the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock worth $56,000 after purchasing an additional 1,218 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new stake in shares of Omnicell in the fourth quarter worth $58,000. Parkside Financial Bank & Trust raised its position in shares of Omnicell by 1,708.1% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock valued at $61,000 after purchasing an additional 1,264 shares during the period. Finally, First Horizon Corp raised its position in shares of Omnicell by 54.6% during the 4th quarter. First Horizon Corp now owns 1,597 shares of the company’s stock valued at $72,000 after purchasing an additional 564 shares during the period. Institutional investors own 97.70% of the company’s stock.

Insider Buying and Selling

In other news, EVP Nnamdi Njoku sold 3,090 shares of the stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $133,549.80. Following the completion of the transaction, the executive vice president directly owned 154,785 shares in the company, valued at approximately $6,689,807.70. This represents a 1.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of the firm’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the transaction, the executive vice president directly owned 112,783 shares of the company’s stock, valued at approximately $4,874,481.26. This trade represents a 4.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is currently owned by corporate insiders.

Omnicell Stock Performance

Shares of NASDAQ OMCL opened at $44.92 on Monday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.29 and a current ratio of 1.50. The company has a market cap of $2.04 billion, a P/E ratio of 102.09, a P/E/G ratio of 1.16 and a beta of 0.96. The firm’s fifty day moving average is $42.24 and its two-hundred day moving average is $41.49. Omnicell, Inc. has a 52-week low of $26.84 and a 52-week high of $55.00.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Tuesday, April 28th. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.33 by $0.22. The business had revenue of $309.88 million during the quarter, compared to the consensus estimate of $304.02 million. Omnicell had a net margin of 1.67% and a return on equity of 4.00%. The business’s revenue was up 14.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.26 EPS. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. As a group, analysts anticipate that Omnicell, Inc. will post 1.31 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on OMCL. Wells Fargo & Company upped their target price on shares of Omnicell from $52.00 to $55.00 and gave the stock an “overweight” rating in a report on Thursday, April 23rd. Weiss Ratings raised Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research note on Thursday, May 7th. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 10th. Craig Hallum reiterated a “buy” rating and set a $55.00 target price on shares of Omnicell in a research report on Wednesday, April 29th. Finally, KeyCorp lifted their target price on Omnicell from $60.00 to $70.00 and gave the company an “overweight” rating in a research note on Tuesday, April 28th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, Omnicell has a consensus rating of “Moderate Buy” and a consensus target price of $59.86.

Omnicell Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.